Palmar plantar erythrodysesthesia classification

Jump to navigation Jump to search

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia classification

CDC on Palmar plantar erythrodysesthesia classification

Palmar plantar erythrodysesthesia classification in the news

Blogs on Palmar plantar erythrodysesthesia classification

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D.

Overview

A number of different classifications have been used for grading the severity of Palmar plantar erythrodysesthesia. The classifications suggested by the National Cancer Institute (NCI), and the World Health Organization are the two most commonly used.

Classification

  • Palmar plantar erythrodysesthesia may be classified into 3 grades according to the National Cancer Institute (NCI).[1]
Classification of PPE severity according to NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0
GRADES
1 Minimal skin changes (e.g, erythema, edema, or hyperkeratosis) without pain
2 Skin changes (e.g, peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting instrumental ADL
3 Severe skin changes (e.g, peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting self care ADL


  • Palmar plantar erythrodysesthesis may be classified into 4 grades based on the World Health Organization. [2]
Classification of PPE severity according to WHO criteria
GRADES
1 Dysesthesia/paresthesia, tingling in the hands and feet
2 Discomfort in holding objects and upon walking, painless swelling or erythema
3 Painful erythema and swelling of palms and soles, periungual erythema and swelling
4 Desquamation, ulceration, blistering, severe pain

Gallery

References

  1. "Protocol Development | CTEP".
  2. Nagore E, Insa A, Sanmartín O (2000). "Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management". Am J Clin Dermatol. 1 (4): 225–34. doi:10.2165/00128071-200001040-00004. PMID 11702367.